News|Articles|October 4, 2023
Using Non-Infectious MVM and RVLP Surrogates to Predict Viral ClearanceInsourcing Purification Workflows Improves Efficiency, Recovery, and Quality
Author(s)Cygnus Technologies
Non-infectious mock virus particles that mimic the physicochemical properties of live infectious viruses can be used as spiking agents during viral clearance testing.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
3
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
4
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
5